Drugs / ETN101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06326502 | Feb 2024 → Mar 2027 expected | hepatocellular carcinoma | Etnova Therapeutics Corp. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ETN101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06326502 ↗ |
| Action | Inhibit | “by blocking the signaling pathway of receptor tyrosine kinases” NCT06326502 ↗ |
| Route | Oral | “Oral administration” NCT06326502 ↗ |
| Target | FLT3 | “ETN101 is a multiple tyrosine kinase inhibitor (mTKI) targeting fms-like tyrosine kinase 3 (FLT3)” NCT06326502 ↗ |
| Target | KIT | “ETN101 is a multiple tyrosine kinase inhibitor (mTKI) targeting fms-like tyrosine kinase 3 (FLT3), receptor tyrosine kinase (KIT)” NCT06326502 ↗ |